Browse > Article
http://dx.doi.org/10.3348/kjr.2011.12.1.34

Computer-Aided Evaluation of Breast MRI for the Residual Tumor Extent and Response Monitoring in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy  

Lyou, Chae-Yeon (Department of Radiology and Clinical Research Institute, Seoul National University Hospital and the Institute of Radiation Medicine, Seoul National University Medical Research Center)
Cho, Nariya (Department of Radiology and Clinical Research Institute, Seoul National University Hospital and the Institute of Radiation Medicine, Seoul National University Medical Research Center)
Kim, Sun-Mi (Department of Radiology, Seoul National University Bundang Hospital)
Jang, Mi-Jung (Department of Radiology, Seoul National University Bundang Hospital)
Park, Jeong-Seon (Department of Radiology, Hanyang University College of Medicine, Hanyang University Hospital)
Baek, Seung-Yon (Department of Radiology, School of Medicine, Ewha Womans University)
Moon, Woo-Kyung (Department of Radiology and Clinical Research Institute, Seoul National University Hospital and the Institute of Radiation Medicine, Seoul National University Medical Research Center)
Publication Information
Korean Journal of Radiology / v.12, no.1, 2011 , pp. 34-43 More about this Journal
Abstract
Objective: To evaluate the accuracy of a computer-aided evaluation program (CAE) of breast MRI for the assessment of residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy. Materials and Methods: Fifty-seven patients with breast cancers who underwent neoadjuvant chemotherapy before surgery and dynamic contrast enhanced MRI before and after chemotherapy were included as part of this study. For the assessment of residual tumor extent after completion of chemotherapy, the mean tumor diameters measured by radiologists and CAE were compared to those on histopathology using a paired student t-test. Moreover, the agreement between unidimensional (1D) measurement by radiologist and histopathological size or 1D measurement by CAE and histopathological size was assessed using the Bland-Altman method. For chemotherapy monitoring, we evaluated tumor response through the change in the 1D diameter by a radiologist and CAE and three-dimensional (3D) volumetric change by CAE based on Response Evaluation Criteria in Solid Tumors (RECIST). Agreement between the 1D response by the radiologist versus the 1D response by CAE as well as by the 3D response by CAE were evaluated using weighted kappa (k) statistics. Results: For the assessment of residual tumor extent after chemotherapy, the mean tumor diameter measured by radiologists (2.0 ${\pm}$ 1.7 cm) was significantly smaller than the mean histological diameter (2.6 ${\pm}$ 2.3 cm) (p = 0.01), whereas, no significant difference was found between the CAE measurements (mean = 2.2 ${\pm}$ 2.0 cm) and histological diameter (p = 0.19). The mean difference between the 1D measurement by the radiologist and histopathology was 0.6 cm (95% confi dence interval: -3.0, 4.3), whereas the difference between CAE and histopathology was 0.4 cm (95% confi dence interval: -3.9, 4.7). For the monitoring of response to chemotherapy, the 1D measurement by the radiologist and CAE showed a fair agreement (k = 0.358), while the 1D measurement by the radiologist and 3D measurement by CAE showed poor agreement (k = 0.106). Conclusion: CAE for breast MRI is sufficiently accurate for the assessment of residual tumor extent in breast cancer patients receiving neoadjuvant chemotherapy. However, for the assessment of response to chemotherapy, the assessment by the radiologist and CAE showed a fair to poor agreement.
Keywords
Breast neoplasm; Chemotherapy; MR imaging; Computer-aided;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 4
연도 인용수 순위
  • Reference
1 Esteva FJ, Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am 1999;13:457-472   DOI
2 Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-2608   DOI   ScienceOn
3 Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004;10:3249-3261   DOI   ScienceOn
4 Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol 2007;37:1-8   DOI
5 Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008;26:791-797   DOI   ScienceOn
6 Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685   DOI
7 Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469   DOI
8 Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100   DOI
9 Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001;7:413-420
10 Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES, et al. Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol 2008;9:10-18   DOI   ScienceOn
11 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216   DOI   ScienceOn
12 Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039   DOI   ScienceOn
13 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247   DOI   ScienceOn
14 Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefi ts of MRI. Breast Cancer Res Treat 2002;72:145-152   DOI   ScienceOn
15 Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78:91-100   DOI   ScienceOn
16 Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JR, Turnbull LW, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001;27:617-620   DOI   ScienceOn
17 Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, et al. Locally advanced breast cancer: contrastenhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994;191:633-638   DOI
18 Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-1999   DOI   ScienceOn
19 Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001;13:868-875   DOI   ScienceOn
20 Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181:1275-1282   DOI   ScienceOn
21 Rieber A, Zeitler H, Rosenthal H, Gorich J, Kreienberg R, Brambs HJ, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70:452-458   DOI
22 Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Lüdemann HP, et al. Accuracy of tumor size measurement in breast cancer using MRI is infl uenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003;13:1213-1223
23 Demartini WB, Lehman CD, Peacock S, Russell MT. Computeraided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy. Acad Radiol 2005;12:806-814   DOI   ScienceOn
24 Wang LC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation. AJR Am J Roentgenol 2009;193:826-831   DOI   ScienceOn
25 Lehman CD, Peacock S, DeMartini WB, Chen X. A new automated software system to evaluate breast MR examinations: improved specifi city without decreased sensitivity. AJR Am J Roentgenol 2006;187:51-56   DOI   ScienceOn
26 American College of Radiology. BIRADS: ultrasound. In: Breast imaging reporting and data system: BIRADS atlas. 4th ed. Reston, VA: American College of Radiology, 2003
27 Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008;28:329-344   DOI   ScienceOn
28 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310
29 Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Ku¨hn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002;12:1711-1719   DOI   ScienceOn
30 Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184:1774-1781   DOI   ScienceOn
31 Hylton N, Blurne J, Bernreuter W, Pisano E, Rosen M, Morris E. MRI assessment of breast cancer response to neoadjuvant chemotherapy: Preliminary findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657 [abstr]. In: Radiological Society of North America scientific assembly and annual meeting program. Available via http://rsna2008.rsna.org/event_display.cfm?em_id=6006524, unpublished data